Eligibility
AccessToTreatment.org is seeking to work with qualified healthcare institutions. They may be governmental, non-governmental, or private. They must be located in eligible countries, and managing programs involved in:
- Care of HIV/AIDS, including ARVs
- Prevention of mother-to-child transmission of HIV (PMTCT)
- Voluntary counseling and testing (VCT)
- Cancer: chronic myeloid leukemia (CML) and/or metastatic malignant gastrointestinal stromal tumours (GISTs) management
The first criterion is geographic. Please check on the eligibility of your institution in your country for the program that interests you.
The approval of the institution by national
authorities is also a prerequisite. Therefore, any
favorable review will be conditional on obtaining/meeting
this condition.
Definition
of a qualified program
The third general criterion is that your institution implement a qualified program in relation to the products for which you are applying. By qualified program we mean the capacity to do the following five things:
- provide adequate services to the patients,
- keep the products safely,
- administer them properly,
- detect side effects and report the serious adverse events, and
- monitor the progress* of the program. (Monitoring means tracking the number of patients and/or clients** included, usage of the products, and reporting this to Axios.)
Review
Criteria
The reviewer will rank the following areas on
the basis of the accuracy and relevance of information provided
by the applicant. The higher the score, the more favorable
the review will be.
Feasibility of Program Implementation
The reviewer will focus on whether the program's scale,
personnel, and budget match its objectives. Reviewers will
also examine the applying institution's capacity to
successfully implement the proposal.
Programmatic Approach or Program Design
It is critical that all clinical aspects (including MTCT programs)
address antenatal care, voluntary counseling and testing (VCT),
delivery of the product, infant feeding strategies, management
of opportunistic infections, and care for both mothers, children,
and adults. The reviewer will ensure that the application
addresses all of these areas. The reviewer may provide additional
technical remarks or scientific opinions, but will not influence
the ranking process.
Logistics and Distribution
The reviewer will focus on procurement, storage and distribution procedures to prevent stock shortages and/or expiration of unused products.
Sustainability
The reviewer will evaluate whether you have designed a lasting
program. While the product donation does not require sustainability,
Axios will critically examine all programs
built on short-term opportunities,to make sure they do not
disrupt existing antenatal healthcare systems.
Any institution having or wishing to initiate
programs on access to HIV care in Africa and the Least Developed
Countries are welcome and encouraged to complete an information
form.
In addition to these general criteria, each
program has specific criteria. Please see below.
If you are uncertain of your eligibility, please
contact us at axios@AccessToTreatment.org
with your details and we will be happy to call you back.
Eligibility
Guidelines Per Program
Diflucan Partnership Program
Thanks to the Diflucan Partnership Program,
Pfizer makes available
free of charge its antifungal medicine, Diflucan®
(fluconazole), to organizations in sub-Saharan Africa and
the Least Developed Countries most in need. Countries with
a greater than 1% HIV/AIDS prevalence will be given priority.
The Diflucan Partnership Program was first implemented
in South Africa in April 2001. October 2002 Pfizer
has partnered with the governments of Botswana, Lesotho, Malawi,
Mozambique, Namibia, Rwanda, Swaziland, Tanzania and Uganda.
See list
of eligible countries per program.
Glivec®
International Patient Assistance Program
The GIPAP model is designed to enable patients
diagnosed with either Philadelphia chromosome–positive
chronic myeloid leukemia (CML) or metastatic malignant gastrointestinal
stromal tumors (GIST) to have access to Glivec®.
GIPAP provides Glivec® at no cost to patients who are:
- Properly diagnosed;
- Not insured;
- Not reimbursed;
- Have no other financial recourse (cannot pay for it privately).
Axios acts as the coordinator
of GIPAP programs in countries where Novartis
has no Country Pharma Organizations (CPOs). Axios
is responsible for identifying and qualifying leading medical
centers in the targeted countries.
Treatment centers are qualified based primarily
on their oncologic/haematologic expertise and diagnostic and
monitoring capabilities. Physicians must be registered in
order to apply for GIPAP assistance on behalf of their patients
to help ensure that appropriate patients for this drug therapy
are considered.
The Max Foundation administers and coordinates
the acceptance and review of applications for inclusion of
patients in GIPAP.
Qualified physicians from your institution who
are interested in applying for GIPAP on behalf of their patients
can obtain an application from www.themaxfoundation.org.
See list
of eligible countries per program.
Viramune Donations for
the Prevention of Mother-To-Child Transmission of HIV
The PMTCT Donations Program is designed to provide
Viramune®
free of charge to sound, sustainable programs aimed at preventing
mother-to-child transmission (PMTCT) in eligible countries.
These programs should 1) provide voluntary counseling and
testing to pregnant women, 2) identify those who are HIV positive,
and 3) provide them with antiretrovirals to prevent mother-to-child transmission of HIV.
See list
of eligible countries per program.
